CATX stock news · Perspective Therapeutics, Inc.
Get alerts for CATX
Follow Perspective Therapeutics, Inc. (CATX) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for CATXPerspective Therapeutics shared new information about its VMT-α-NET trial at the NANETS 2026 symposium.
NeutralPerspective Therapeutics shared new analyses from its VMT-α-NET Phase 1/2a trial, but the filing gives no outcomes. That leaves the company's outlook unchanged.
Perspective Therapeutics shares results from its clinical trial and holds a conference call to discuss them.
Good for CATXPerspective Therapeutics reported initial responses in 50% of Cohort 3 patients and disease control in 95%, with no Grade 4 or 5 events reported. These findings support a positive outlook.
Perspective Therapeutics, Inc. shares news about new results from its clinical trial for treating neuroendocrine tumors.
NeutralPerspective Therapeutics filed an update about interim trial results, but the filing text gives no findings. It does not show a clear change in the company's outlook.
Perspective Therapeutics, Inc. says the FDA gave Fast Track status to its drug PSV359 for treating some tumors.
Good for CATXThe FDA granted Fast Track status to CATX's PSV359 for a rare tumor. This supports the drug's development, but does not mean it is approved.
Perspective Therapeutics, Inc. shared news about its company update on October 1, 2026.
NeutralPerspective Therapeutics updated its corporate presentation, but the filing gives no details about the changes. This provides no clear reason to change the company's outlook.
Perspective Therapeutics, Inc. shares news about its company update.
NeutralPerspective Therapeutics filed an updated corporate presentation on Form 8-K. The filing is administrative and reports no new clinical or financial data, so it does not change the company's outlook.